Beijing FDA Gives Quick Nod For H7N9 Rapid Testing Agent
This article was originally published in PharmAsia News
A H7N9 diagnostic testing agent developed by Beijing Kinghawk Pharmaceutical Co. Ltd and Beijing SinoMedgene Technology Co. Ltd. was approved by Beijing FDA under the green channel approval process. The test cuts the time for results to less than three hours, down from six hours.
You may also be interested in...
Beijing Quietly Charms Both MNCs And Specialty Biotechs In Effort To Establish China's Bio Valley
BEIJING - Aiming to carve a leading position in China's nascent biotech industry, Beijing has embarked on a project to grow the industry more than two-fold in three years. Dubbed the "G20 Project," the Beijing Leap-forward Development Program for Biopharmaceutical Industry seeks to transform the capital city into China's hub for biotech R&D and manufacturing
Big Pharma CEOs Suggest Policy Changes As They Return To Beijing
Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.
Chinese Biopharma Tycoons Down But Not Out In Latest Global Billionaire Ranking
China continues to dominate the latest list of global billionaires and top execs from domestic pharma firms Hengrui and Hansoh ranked among the wealthiest overall in the country, along with the founder of vaccine maker Zhifei Bio. A number of top Chinese biopharma business executives also featured in the global top 100 billionaires list.